Excerpt from Journal for Clinical Studies' Article "Policy 0070 Under the Microscope: The Trade-off Between Clinical Trial Transparency and the Risk of Revealing Patient Identities" by Cathal Gallagher | February 24, 2017Read Article Now
d-Wise's Insight on Journal for Clinical Studies' Article
Contesting EMA expectations won’t do companies any favours, certainly. EMA has already demonstrated its intention to stand its ground in the European law courts4, confirming plans to appeal against initial court rulings that decided in favour of corporate privacy.
The life sciences industry has enough battles on its hands at the moment; arguing against the greater good of patients shouldn’t be one of them.